Effect of naltrexone on senile dementia of the Alzheimer type

Bradley T. Hyman, Paul J. Eslinger, Antonio R. Damasio

Research output: Contribution to journalArticle

20 Scopus citations


Some reports have suggested that naloxone, a short-acting opiate receptor blocker given intravenously, has a beneficial effect on the symptoms of senile dementia of the Alzheimier type. We have performed a double-blind, crossover trial of naltrexone, an orally active, long acting opiate antagonist, in 17 Alzheimer-type dementia patients. None showed any improvement in assessments of day-to-day living skills or on a battery of neuropsychological tests. No side effects were noted. In the dosage used, naltrexone appears not to be useful in Alzheimer-type dementia.

Original languageEnglish (US)
Pages (from-to)1169-1171
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Issue number11
Publication statusPublished - Jan 1 1985


All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this